Insider Trading Activity Nabriva Therapeutics AG (NASDAQ:NBRV) – Ca (Major Shareholder Sold 6,585 shares of Stock

ME Staff
-
0

Insider Trading Activity For Nabriva Therapeutics AG (NASDAQ:NBRV)

Hbm Healthcare Investments , Ca (Major Shareholder of Nabriva Therapeutics AG (NASDAQ:NBRV) reportedly Sold 6,585 shares of the company’s stock at an average price of 10.51 for a total transaction amount of $69,208.35 SEC Form

Insider Trading History For Nabriva Therapeutics AG (NASDAQ:NBRV)

  • On 4/10/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 90,594 with an average share price of $10.96 per share and the total transaction amounting to $992,910.24.View SEC Filing
  • On 4/13/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 32,831 with an average share price of $11.24 per share and the total transaction amounting to $369,020.44.View SEC Filing
  • On 4/20/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 23,932 with an average share price of $11.11 per share and the total transaction amounting to $265,884.52.View SEC Filing
  • On 4/21/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 2,622 with an average share price of $11.04 per share and the total transaction amounting to $28,946.88.View SEC Filing
  • On 4/28/2017 Hbm Healthcare Investments (Ca, Major Shareholder, sold 15,939 with an average share price of $11.02 per share and the total transaction amounting to $175,647.78.View SEC Filing
  • On 5/15/2017 George Harrison Talbot, Director, sold 50 with an average share price of $101.50 per share and the total transaction amounting to $5,075.00.View SEC Filing
  • On 5/16/2017 George Harrison Talbot, Director, sold 200 with an average share price of $102.44 per share and the total transaction amounting to $20,488.00.View SEC Filing

    • Analyst Ratings For Nabriva Therapeutics AG (NASDAQ:NBRV)
    These are 6 Buy Ratings .
    The current consensus rating for Nabriva Therapeutics AG (NASDAQ:NBRV) is Buy (Score: 3.00) with a consensus target price of $16.00 , a potential (67.54% upside)

    Analyst Ratings History For Nabriva Therapeutics AG (NASDAQ:NBRV)

    • On 1/27/2016 Gabelli Initiated Coverage of rating Buy with a price target of $14.00
    • On 10/27/2016 Leerink Swann Reiterated Rating Outperform with a price target of $14.00
    • On 12/20/2016 Royal Bank of Canada Set Price Target of rating Buy with a price target of $22.00
    • On 3/27/2017 Needham & Company LLC Reiterated Rating Buy with a price target of $15.00
    • On 5/15/2017 Wedbush Reiterated Rating Outperform with a price target of $13.00
    • On 6/30/2017 HC Wainwright Reiterated Rating Buy with a price target of $16.00
    • On 7/11/2017 Cantor Fitzgerald Set Price Target of rating Buy with a price target of $16.00

    Recent Trading Activity for Nabriva Therapeutics AG (NASDAQ:NBRV)
    Shares of Nabriva Therapeutics AG closed the previous trading session at 9.55 down -0.93 -8.87% with 27,457 shares trading hands.